ES2375614T3 - Derivados de espiro tric�?clicos como moduladores de crth2 - Google Patents

Derivados de espiro tric�?clicos como moduladores de crth2 Download PDF

Info

Publication number
ES2375614T3
ES2375614T3 ES06763238T ES06763238T ES2375614T3 ES 2375614 T3 ES2375614 T3 ES 2375614T3 ES 06763238 T ES06763238 T ES 06763238T ES 06763238 T ES06763238 T ES 06763238T ES 2375614 T3 ES2375614 T3 ES 2375614T3
Authority
ES
Spain
Prior art keywords
chloro
indole
pyrrolidin
acetic acid
trioxospiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06763238T
Other languages
English (en)
Spanish (es)
Inventor
Matthias Schwarz
Eric Sebille
Christophe Cleva
Cedric Merlot
Dennis Church
Patrick Page
Jacqueline A. Macritchie
John Frederick Atherall
Stefano Crosignani
Doris Pupowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Application granted granted Critical
Publication of ES2375614T3 publication Critical patent/ES2375614T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES06763238T 2005-05-24 2006-05-23 Derivados de espiro tric�?clicos como moduladores de crth2 Active ES2375614T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05104428 2005-05-24
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08
US688631P 2005-06-08
PCT/EP2006/062545 WO2006125784A1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as crth2 modulators

Publications (1)

Publication Number Publication Date
ES2375614T3 true ES2375614T3 (es) 2012-03-02

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06763238T Active ES2375614T3 (es) 2005-05-24 2006-05-23 Derivados de espiro tric�?clicos como moduladores de crth2

Country Status (20)

Country Link
US (1) US8236963B2 (enExample)
EP (1) EP1891075B1 (enExample)
JP (1) JP5567268B2 (enExample)
KR (1) KR101333861B1 (enExample)
CN (1) CN101300259B (enExample)
AR (1) AR055959A1 (enExample)
AT (1) ATE529429T1 (enExample)
AU (1) AU2006251138C1 (enExample)
BR (1) BRPI0610209A2 (enExample)
CA (1) CA2602965C (enExample)
DK (1) DK1891075T3 (enExample)
ES (1) ES2375614T3 (enExample)
MX (1) MX2007014256A (enExample)
NZ (1) NZ562772A (enExample)
PL (1) PL1891075T3 (enExample)
PT (1) PT1891075E (enExample)
RU (1) RU2478639C2 (enExample)
UA (1) UA90145C2 (enExample)
WO (1) WO2006125784A1 (enExample)
ZA (1) ZA200709819B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448092C2 (ru) 2006-08-07 2012-04-20 Актелион Фармасьютиклз Лтд Производные (3-амино-1,2,3,4-тетрагидро-9н-карбазол-9-ил)уксусной кислоты
AU2010272524A1 (en) 2009-07-15 2012-02-02 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as CRTH2 modulators
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールmdm2アンタゴニスト
US8697869B2 (en) 2010-03-22 2014-04-15 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
UY33725A (es) 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
MX338516B (es) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
MX346375B (es) 2011-05-11 2017-03-16 Univ Michigan Regents Antagonistas de espiro-oxindol de mdm2.
CA2859284A1 (en) 2011-12-16 2013-06-20 Atopix Therapeutics Limited Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
MX384987B (es) 2014-03-17 2025-03-14 Idorsia Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores de receptor de prostaglandina d2.
BR112016021443A8 (pt) 2014-03-18 2017-12-26 Actelion Pharmaceuticals Ltd Derivados de ácido acético azaindol e seu uso como moduladores de receptor de prostaglandina d2
BR112017019453A2 (pt) 2015-03-13 2018-05-15 Forma Therapeutics Inc compostos e composições de alfa-cinamida como inibidores de hdac8
CA2984711C (en) 2015-07-15 2023-08-29 F. Hoffmann-La Roche Ag Ethynyl derivatives as metabotropic glutamate receptor modulators
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
CN109476671B (zh) 2016-07-18 2021-09-24 豪夫迈·罗氏有限公司 乙炔基衍生物
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
AU2019413360B2 (en) 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
HUP0202248A3 (en) * 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
GB2388540A (en) * 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
BR0315547A (pt) 2002-10-21 2005-09-20 Warner Lambert Co Derivados de quinolina como antagonistas de crth2
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
MXPA06011891A (es) 2004-04-20 2007-04-24 Pfizer Metodo para tratar el dolor neuropatico.

Also Published As

Publication number Publication date
EP1891075B1 (en) 2011-10-19
AR055959A1 (es) 2007-09-12
CN101300259B (zh) 2013-08-28
ATE529429T1 (de) 2011-11-15
AU2006251138C1 (en) 2013-08-29
JP5567268B2 (ja) 2014-08-06
CA2602965C (en) 2013-12-31
CN101300259A (zh) 2008-11-05
RU2478639C2 (ru) 2013-04-10
CA2602965A1 (en) 2006-11-30
AU2006251138B2 (en) 2012-08-09
KR20080031191A (ko) 2008-04-08
PL1891075T3 (pl) 2011-12-30
EP1891075A1 (en) 2008-02-27
BRPI0610209A2 (pt) 2010-06-01
UA90145C2 (ru) 2010-04-12
KR101333861B1 (ko) 2013-11-28
NZ562772A (en) 2010-01-29
DK1891075T3 (da) 2011-12-19
US20090318486A1 (en) 2009-12-24
ZA200709819B (en) 2009-09-30
US8236963B2 (en) 2012-08-07
AU2006251138A1 (en) 2006-11-30
MX2007014256A (es) 2008-03-26
JP2008542238A (ja) 2008-11-27
PT1891075E (pt) 2011-11-10
WO2006125784A1 (en) 2006-11-30
RU2007147430A (ru) 2009-06-27

Similar Documents

Publication Publication Date Title
ES2375614T3 (es) Derivados de espiro tric�?clicos como moduladores de crth2
RU2571100C2 (ru) Спироиндолинонпирролидины, полезные при лечении злокачественных новообразований
US8431565B2 (en) Substituted imidazoheterocycles
ES2389907T3 (es) Compuesto de amida heterocíclica y uso del mismo como un inhibidor de MMP-13
ES2403284T3 (es) Pirimidil ciclopentanos como inhibidores de la proteína quinasa AKT
KR101331771B1 (ko) 베타 3 아드레날린성 수용체 효능제로서의 하이드록시메틸 피롤리딘
CN105473550A (zh) Ido抑制剂
ES2745284T3 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
HUE035292T2 (en) vegf-r2 inhibitor pyridyl oxindoles and their use in the treatment of disease
KR20080087070A (ko) 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제
KR20160055190A (ko) 트립토판 하이드록실레이스 억제제로서 스파이로사이클릭 화합물
TW201107335A (en) Compounds-801
US8835422B2 (en) Substituted imidazoheterocycle derivatives
CN118139862A (zh) 含氮杂环类化合物及其医药用途
CN120225525A (zh) 用于调节her2的化合物及方法
TW201607941A (zh) T型鈣通道阻礙劑
JP2023546226A (ja) 統合ストレス応答経路のモジュレーター
TWI357897B (en) 3-substituted-5- and 6-aminoalkyl indole-2-carboxy
HK1121146A1 (en) Tricyclic spiro derivatives as crth2 modulators
HK1121146B (en) Tricyclic spiro derivatives as crth2 modulators
WO2024240086A1 (zh) 一种调控15-pgdh活性的化合物及其制备方法
TW202440084A (zh) 作為trpa1抑制劑之雙環醯亞胺化合物